(R)-2-((R)-3-benzyloxy-1-hydroxypropyl)pent-4-enoic acid methyl ester | 1192146-50-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-((R)-3-benzyloxy-1-hydroxypropyl)pent-4-enoic acid methyl ester
• 英文别名: methyl (2R)-2-[(1R)-1-hydroxy-3-phenylmethoxypropyl]pent-4-enoate
• CAS: 1192146-50-1
• 化学式: C₁₆H₂₂O₄
• 分子量: 278.348
• InChiKey: GEHPJZXDXWTHBW-HUUCEWRRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-2-((R)-3-benzyloxy-1-hydroxypropyl)pent-4-enoic acid methyl ester 、 叔丁基二甲基氯硅烷 在 咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以87%的产率得到(R)-2-[(R)-3-benzyloxy-1-(tert-butyldimethylsilanyloxy)-propyl]pent-4-enoic acid methyl ester
  参考文献：
  名称：

  The synthesis of single enantiomers of mycobacterial ketomycolic acids containing cis-cyclopropanes

  摘要：

  We report the syntheses of a single enantiomer of an unprotected ketomycolic acids containing a cis-cyclopropane and of related hydroxy-mycolic acids. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2009.09.099
• 作为产物：
  描述：

  丙烯酰碘 、 (3R)-hydroxy-5-benzyloxy-pentanoic acid methyl ester 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 六甲基磷酰三胺 为溶剂， 反应 2.0h， 以76%的产率得到(R)-2-((R)-3-benzyloxy-1-hydroxypropyl)pent-4-enoic acid methyl ester
  参考文献：
  名称：

  The synthesis of single enantiomers of mycobacterial ketomycolic acids containing cis-cyclopropanes

  摘要：

  We report the syntheses of a single enantiomer of an unprotected ketomycolic acids containing a cis-cyclopropane and of related hydroxy-mycolic acids. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2009.09.099

文献信息

• Compounds for Use in Therapy
  申请人：Baird Mark Stephen

  公开号：US20110150981A1

  公开（公告）日：2011-06-23

  A compound of formula (I) for use in the treatment of a disease of the immune system; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R 1 is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 40 carbon atoms; each of R 2 , Wand R 4 is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, arylalkylene or alkylarylene moiety having from 1 to 40 carbon atoms; each of X, Y and Z is independently selected from an optionally-substituted alkylene, alkenylene, alkenylene, arylene, alkylarylene, cycloalkylene, ketone, ester, amide, imide, imine, thioether, ether, thioester and thioketone; and P is selected from hydrogen, an alkyl group, a sugar residue, or a metal, phosphonium or ammonium species; wherein at least one of X, Y and Z includes a moiety selected from cyclopropyl, C=A, C-AH and C-OR 5 ; wherein R 5 is alkyl or haloalkyl, and A is O, S or Me, wherein R 6 may be H or 20 alkyl.

  化合物式（I）的化合物用于治疗免疫系统疾病；其中R是具有1至50个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；R1是具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；R2，W和R4中的每一个都独立地选择自具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团的取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；X，Y和Z中的每一个都独立地选择自可选取代的烷基，烯基，烯基，芳基，烷基芳基，环烷基，酮，酯，酰胺，亚酰胺，亚胺，硫醚，醚，硫酯和硫酮的基团；P从氢，烷基，糖残基或金属，膦，铵或铵物种中选择；其中X，Y和Z中至少有一个包括从环丙基，C = A，C-AH和C-OR5中选择的基团；其中R5是烷基或卤代烷基，A是O，S或Me，R6可能是H或20烷基。
• Adjuvants for Use in Vaccination
  申请人：Baird Mark Stephen

  公开号：US20110142916A1

  公开（公告）日：2011-06-16

  A compound of formula (I) for use as an adjuvant in vaccination; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R 1 is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 40 carbon atoms; each of R 2 , R 3 and R 4 is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, arylalkylene or alkylarylene moiety having from 1 to 40 carbon atoms; each of X, Y and Z is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, alkylarylene or cycloalkylene, ketone, ester, amide, imide, imine, thioether, ether, thioester, thioketone; and P is selected from hydrogen, an alkyl group, a sugar residue, or a metal, phosphonium or ammonium species; wherein at least one of X, Y and Z includes a moiety selected from cyclopropyl, C=A, C-AH and C—OR 5 ; wherein R 5 is alkyl or haloalkyl, and A is S, O or NR 6 , wherein R 6 maybe H or 20 alkyl.

  化合物式（I）的复合物用作疫苗佐剂；其中R是具有1至50个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团; R1是具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团; R2，R3和R4中的每一个都是独立选择的，具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团; X，Y和Z中的每一个都是独立选择的，具有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，烷基芳基或环烷基，酮，酯，酰胺，亚酰胺，亚胺，硫醚，醚，硫酯，硫酮; P是氢，烷基，糖残基或金属，膦或铵物种中的一种；其中X，Y和Z中至少一个包括从环丙基，C=A，C-AH和C—OR5中选择的基团; 其中R5是烷基或卤代烷基，A是S，O或NR6，其中R6可以是H或20烷基。
• Compounds for use in therapy
  申请人：Baird Mark Stephen

  公开号：US08889894B2

  公开（公告）日：2014-11-18

  A compound of formula (I) for use in the treatment of a disease of the immune system; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R1 is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 40 carbon atoms; each of R2, R3 and R4 is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, arylalkylene or alkylarylene moiety having from 1 to 40 carbon atoms; each of X, Y and Z is independently selected from an optionally-substituted alkylene, alkenylene, alkenylene, arylene, alkylarylene, cycloalkylene, ketone, ester, amide, imide, imine, thioether, ether, thioester and thioketone; and P is selected from hydrogen, an alkyl group, a sugar residue, or a metal, phosphonium or ammonium species; wherein at least one of X, Y and Z includes a moiety selected from cyclopropyl, C=A, C-AH and C—OR5; wherein R5 is alkyl or haloalkyl, and A is O, S or NR6, wherein R6 may be H or 20 alkyl.

  一种化合物的化学式（I），用于治疗免疫系统疾病；其中R是具有1-50个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；R1是具有1-40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；R2，R3和R4中的每一个都是独立选择的，选自具有1-40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；X，Y和Z中的每一个都是独立选择的，选自具有1-40个碳原子的可选取代的烷基，烯基，炔基，芳基，烷基芳基，环烷基，酮，酯，酰胺，亚酰胺，亚胺，硫醚，醚，硫代酯和硫代酮；P选自氢，烷基，糖残基或金属，膦或铵物种；其中X，Y和Z中至少一个包括从环丙基，C = A，C-AH和C-OR5中选择的基团；其中R5是烷基或卤代烷基，A是O，S或NR6，其中R6可以是H或20烷基。
• Adjuvants for use in vaccination
  申请人：Baird Mark Stephen

  公开号：US08728515B2

  公开（公告）日：2014-05-20

  A compound of formula (I) for use as an adjuvant in vaccination; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon atoms; R1 is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 40 carbon atoms; each of R2, R3 and R4 is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, arylalkylene or alkylarylene moiety having from 1 to 40 carbon atoms; each of X, Y and Z is independently selected from an optionally-substituted alkylene, alkenylene, alkynylene, arylene, alkylarylene or cycloalkylene, ketone, ester, amide, imide, imine, thioether, ether, thioester, thioketone; and P is selected from hydrogen, an alkyl group, a sugar residue, or a metal, phosphonium or ammonium species; wherein at least one of X, Y and Z includes a moiety selected from cyclopropyl, C=A, C-AH and C—OR5; wherein R5 is alkyl or haloalkyl, and A is S, O or NR6, wherein R6 maybe H or 20 alkyl.

  式(I)的化合物作为疫苗佐剂使用；其中R是含有1至50个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；R1是含有1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；R2，R3和R4中的每一个都独立地选择自1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团的取代的烷基，烯基，炔基，芳基，芳基烷基或烷基芳基基团；X，Y和Z中的每一个都独立地选择自1至40个碳原子的可选取代的烷基，烯基，炔基，芳基，烷基芳基或环烷基，酮，酯，酰胺，咪唑，亚胺，硫醚，醚，硫酯，硫酮；P选择自氢，烷基，糖残基或金属，膦或铵物种；其中X，Y和Z中至少一个包括从环丙基，C=A，C-AH和C—OR5中选择的基团；其中R5是烷基或卤代烷基，A是S，O或NR6，其中R6可以是H或20烷基。
• US8728515B2
  申请人：——

  公开号：US8728515B2

  公开（公告）日：2014-05-20